Pyroptosis‐Inducing Engineered Microparticles for Cancer Immunotherapy
Advanced Science · 2026-06 · 13 (31)
DOI: 10.1002/advs.74886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 18.03.2026. Verfasst von Tianli Hao und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China. Hauptthemen laut MEDLINE: Immunotherapy, Pyroptosis, Neoplasms. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Hubei Provincial University Excellent Young and Middle-aged Scientific and Technological Innovation Team Plan Project.
Abstract (Originalsprache)
Pyroptosis, a form of immunogenic cell death, can remodel the immunosuppressive tumor microenvironment; however, its clinical translation is challenged by difficulties in targeted induction and biosafety concerns. In this study we discovered that geldanamycin (GA) can interacts specifically with arginine 207 (R207) in caspase‑3, and efficiently cleaved caspase‐3, significantly inducing high‐efficiency pyroptosis. Although high‐dose GA promoted pyroptosis and antitumor immunity, physiological toxicity and the induction of resistance mediated by immune checkpoints including PD‐L1 and CD47 limited therapeutic efficacy. To address this, we developed biomimetic dual‐targeting microparticles(MPs)functionalized with anti‐PD‐L1 and anti‐SIRPα nanobodies. This strategy synergized targeted pyroptosis induction with dual immune checkpoint blockade, achieving complete tumor regression, reduced physiological toxicity, and induced a potent effector immune response in murine cancer models, presenting a promising combinatorial approach for lung cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
- NHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, Hainan Medical University, Haikou, Hainan, China.
- Department of Biomedical Engineering, University At Buffalo, State University of New York, Buffalo, New York, USA.
- Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Muyang Yang, Jonathan F Lovell, Yushuai Liu, Honglin Jin
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Hubei Provincial University Excellent Young and Middle-aged Scientific and Technological Innovation Team Plan Project
Zitieren
APA
Hao, T., Deng, Z., Liu, Y., Liu, L., Deng, D., Yang, M., Geng, Y., Sun, Y., Yue, B., Lovell, J. F., Liu, Y., Lu, L., & Jin, H. (2026). Pyroptosis‐Inducing Engineered Microparticles for Cancer Immunotherapy. Advanced Science, 13(31). https://doi.org/10.1002/advs.74886
Vancouver
Hao T, Deng Z, Liu Y, Liu L, Deng D, Yang M, et al. Pyroptosis‐Inducing Engineered Microparticles for Cancer Immunotherapy. Advanced Science. 2026;13(31). doi:10.1002/advs.74886
BibTeX
@article{Hao2026,
author = {Hao, Tianli and Deng, Zihan and Liu, Yufei and Liu, Li and Deng, Deqiang and Yang, Muyang and Geng, Yuanyuan and Sun, Yao and Yue, Beilei and Lovell, Jonathan F and Liu, Yushuai and Lu, Lisen and Jin, Honglin},
title = {Pyroptosis‐Inducing Engineered Microparticles for Cancer Immunotherapy},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {31},
doi = {10.1002/advs.74886}
}
EUVIMED